Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Insight Partners in connection with its investment by participation in a MSEK 190 investment round in Insurely
Mandate

Vinge has advised Insight Partners in connection with its investment by participation in a MSEK 190 investment round in Insurely

March 08, 2022 Employment and Benefits Insurance Law IT, Telecommunications and Outsourcing M&A Corporate Crime & Compliance Financial Regulatory Intellectual Property

Vinge has advised Insight Partners in connection with its investment by participation in a MSEK 190 investment round in Insurely. Insurely offers a digital platform which gives insurance policyholders easy access to an overview of their insurance policies.

Vinge’s team consisted of Christina Kokko, Johan Larsson, Isabelle Wållgren and Nando Basic (M&A), Viveka Classon and Elin Samara (Insurance regulatory), Fredrika Hjelmberg (IT), Nicklas Thorgerzon (GDPR), Elin Broman (Employment), Axel Lennartsson (IPR), Tove Tullberg (Compliance) and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025